Bristol-Myers Squibb: Key takeaways from BMY Pipelines Unplugged with CMO

Research evidence excerpt

Bristol-Myers Squibb: Key takeaways from BMY Pipelines Unplugged with CMO

CELMoDs (MM): ASCO will make the case for replacement

Revlimid and Pomalyst (IMiDs) totaled >$15bn peak sales; BMY aspires to replace them

with CELMoDs iberdomide and mezigdomide. At ASCO investors will see first results for

mezi (SUCCESSOR-2), and BMY believes investors will leave assured that mezi will beat

Pomalyst in the SUCCESSOR-1 trial. BMY is not worried about iber approval on MRD(-),

and hints that PFS (the usual endpoint) will be available soon. Revlimid maintenance

comprised most the $15bn peak, thus the importance of the iber EXCALIBUR-

Maintenance H2H against Revlimid. BMY maintains Revlimid is the mainstay of

maintenance, saying Darzalex/Revlimid maintenance is a minority practice (although use

is increasing).

Pumitamig (solid tumors): NSCLC validation at ASCO

BMY would not be drawn into a discussion about competitor ivonescimab (OS at ASCO),

preferring to look at its own data from the global ROSETTA-Lung02 trial, data to be

presented at ASCO including first data in NSQ NSCLC. BMY frames pumitamig as an

anchor in oncology, starting in tumors sensitive to either PDx or VEGF. Iza-bren ADC and

PRMT5 as top-of-mind combination partners for the next wave of “novel/novel” trials.

BMY is conducting a series of combination trials looking at many permutations across its

portfolio, then advancing the winners. Partner BNTX can also be a source of

combination partners.

Abbreviations

ADC: antibody-drug conjugate

ADP: Alzheimer’s disease psychosis

AF: atrial fibrillation

ASCO: American Society of Clinical Oncology

BID: twice daily

BNTX: BioNTech

CELMoD/IMiD: drug platform

CRNM: clinically-relevant non-major bleed

DDI: drug-drug interaction

DSMB: data-safety monitoring board

GI: gastrointestinal